Other
Dec 2024BioAge discontinued the STRIDES Phase 2 obesity trial of azelaprag after transaminitis/liver-enzyme elevations were observed in some participants; dosing stopped and the company said it would reassess the program.
SourceClinical-stage biotech developing therapies for aging.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Clinical-stage biopharmaceutical company using longitudinal human-aging data and multi-omics to develop therapies for metabolic disease; lead asset BGE-102 is an oral, brain-penetrant NLRP3 inhibitor for cardiovascular risk and retinal disease. Public GitHub not found.
Primary product
BGE-102, an orally available, brain-penetrant small-molecule NLRP3 inhibitor
Founded
2015
Headquarters
Emeryville, California, United States
Team size
51-200
Work style
Remote
Industry
Biotechnology Research
Sub-industry
Clinical-stage cardiometabolic therapeutics
Offices
Open Positions
0 jobs at BioAge Labs
No open positions
Check back later for new openings